Aprea Therapeutics (NASDAQ:APRE) vs. Vivesto (OTCMKTS:OASMY) Head to Head Comparison

Vivesto (OTCMKTS:OASMY) and Aprea Therapeutics (NASDAQ:APRE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Institutional & Insider Ownership

34.2% of Aprea Therapeutics shares are held by institutional investors. 12.8% of Aprea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Vivesto and Aprea Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivesto	$100,000.00	N/A	-$35.35 million	N/A	N/A
Aprea Therapeutics	$580,000.00	38.48	-$14.29 million	($3.32)	-1.24

Aprea Therapeutics has higher revenue and earnings than Vivesto.

Risk and Volatility

Vivesto has a beta of 22.24, suggesting that its share price is 2,124% more volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Profitability

This table compares Vivesto and Aprea Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivesto	N/A	N/A	N/A
Aprea Therapeutics	-1,317.82%	-56.78%	-46.12%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Vivesto and Aprea Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivesto	0	0	0	0	N/A
Aprea Therapeutics	0	0	2	0	3.00

Aprea Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 277.13%. Given Aprea Therapeutics’ higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Vivesto.

Summary

Aprea Therapeutics beats Vivesto on 6 of the 10 factors compared between the two stocks.

About Vivesto

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

About Aprea Therapeutics

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.